https://grafa.com/en/news/australia/neuren-shares-rise-on-record-daybue-sales-growth
Neuren shares rise on record DAYBUE sales growth | Grafa
May 7, 2026 - Neuren Pharmaceuticals (ASX:NEU) reported net sales of its flagship Rett syndrome treatment, DAYBUE (trofinetide) in Q1.
on recordsales growthsharesrisedaybue
https://druganalyst.com/Acadia/Daybue
Daybue (trofinetide) - Acadia Sales History and Forecasts - DRUGANALYST
sales historydaybueacadiaforecasts